As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices ...
The Health and Human Services Department won’t issue health advisories, reports or other materials until further notice, with ...
As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, ...
Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and ...
(HealthDay News) — Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in a news ...
The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...
The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started ...
Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in ...
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...
Meena Seshamani’s Medicare swan song ended on a note of bravura: the announcement that 15 costly drugs, including Novo ...
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
The exact scope and duration is clear, and one question is what will happen to release of CDC data that employers and insurers use in pricing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback